Educational interventions to improve quality of life in people with chronic inflammatory skin diseases: systematic reviews of clinical effectiveness and cost-effectiveness

Karen Pickett, Emma Loveman,* Neelam Kalita, Geoff K Frampton and Jeremy Jones

Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, Southampton, UK

*Corresponding author

Declared competing interests of authors: none

Published October 2015 DOI: 10.3310/hta19860

Scientific summary

Educational interventions for people with chronic inflammatory skin diseases

Health Technology Assessment 2015; Vol. 19: No. 86 DOI: 10.3310/hta19860

NIHR Journals Library www.journalslibrary.nihr.ac.uk

Scientific summary

Background

Inflammatory skin diseases include a broad range of disorders of the skin. The most commonly recorded conditions are eczema, psoriasis and acne. People with chronic inflammatory skin diseases experience symptoms including itching, dry skin and changes in skin appearance to varying degrees of severity and bodily involvement. For some people, these conditions lead to high levels of psychological comorbidities and reduced quality of life (QoL). Patient education – typically defined as providing patients with information about, and training in, skills for managing their condition – is a recommended part of the management of chronic inflammatory skin conditions and may improve QoL. As part of these interventions, patients are often provided with information about their condition and the use of treatments. However, it has been suggested that the inclusion of additional elements in these interventions that specifically address issues related to poor QoL may enhance the impact of educational interventions on QoL. Although such interventions are available to some people with these conditions, their clinical effectiveness and cost-effectiveness is unclear.

Objectives

To undertake systematic reviews of the clinical effectiveness and cost-effectiveness of educational interventions for improving health-related quality of life (HRQoL) in people with chronic inflammatory skin diseases and to make recommendations for future research.

Methods

Electronic bibliographic resources, including MEDLINE, EMBASE, The Cochrane Library, Cumulative Index to Nursing and Allied Health Literature, and PsycINFO, were searched for published studies from inception to July 2014 for English language articles. Bibliographies of included articles and systematic reviews were also searched for additional studies. An Advisory Group was contacted to identify additional published and unpublished evidence.

Study selection

Titles and abstracts were independently screened for eligibility by two reviewers. Inclusion criteria were applied to full texts by one reviewer and checked by a second reviewer. Inclusion criteria were as follows:

- Population: adults, young people and children with a chronic inflammatory skin condition and/or their carers.
- Intervention: educational interventions that either specifically aim to improve HRQoL or could improve HRQoL.
- Comparators: any comparator was eligible.
- Outcomes: only studies that measured HRQoL as an outcome, using a validated measure, were included. Data were also extracted on outcomes, including measures of disease severity, disease control and scratching behaviour. Patient-assessed subjective outcome measures were included if assessed by validated tools.

- Studies were included in the systematic review of clinical effectiveness if they were randomised controlled trials (RCTs). If no RCT evidence was available, prospective trials with one or more concurrent control groups were eligible.
- Studies were included in the systematic review of cost-effectiveness if they were full economic evaluations (cost-effectiveness, cost-utility or cost-benefit analyses), cost-consequence analyses or cost analyses.

Full-text papers were included only if they reported results in sufficient detail. Abstracts or conference presentations were eligible for inclusion only if sufficient details of methods and results were presented.

Data extraction and quality assessment

Data extraction and quality assessment were undertaken by one reviewer and checked by a second reviewer. Differences in opinion were resolved by discussion at each stage.

Data synthesis

Data were synthesised through narrative reviews with tabulation of the results of included studies.

Results

Clinical effectiveness

From 2628 references, 63 were retrieved for consideration. Seven RCTs were included (one additional study, a controlled clinical trial, met the inclusion criteria, but was not reviewed, in line with the review protocol). Two RCTs assessed the effects of educational interventions for adults with psoriasis, one RCT assessed an education intervention for women with acne and two RCTs assessed the effects of educational interventions in children with eczema and/or their carers. Two further RCTs focused on adults with mixed skin conditions, one on those a range of pruritic skin conditions and the second on those with either psoriasis or eczema (and results for these subgroups were provided). There were few similarities between studies in terms of the interventions. The delivery mode (e.g. group or individual; face to face, online or via text messaging), the topics covered, the provider of the education, and the duration and intensity of the education differed between studies. There were also few similarities in the choices of outcome measures employed, although all studies reported HRQoL, most often with the Dermatology Life Quality Index. Follow-up ranged from 4 weeks to 12 months. The guality of the included RCTs was generally poor. Sample sizes were generally small; in one study, there was a large sample size, but results were reported for a number of different, smaller, subgroups. Three studies were reported to be pilot studies. Only two studies were based in the UK and the findings of the majority of the trials were considered to be of limited generalisability to the UK.

Three RCTs found statistically significant improvements in HRQoL. In RCTs of participants with psoriasis, the effect of the educational interventions on HRQoL appeared to be positive in two trials (one was a subgroup) when this was measured at the end of the 3-month interventions, with positive effects on one of two HRQoL measures used persisting 6 months after the intervention in the one RCT with a longer-term follow-up. In a pilot RCT of participants with mild-to-moderate psoriasis there was no statistically significant impact on HRQoL at 6 weeks' follow-up. One RCT investigated the impact of an educational intervention on children and their carers and adolescents with eczema in three age-related subgroups. HRQoL appeared to be improved in the carers of children in two age groups (3 months to 7 years and 8–12 years). HRQoL was not measured in the adolescent group (participants or carers). Another RCT evaluating an educational website for carers of children aged up to 5 years with eczema found no effects on HRQoL. An additional RCT reported on a small subgroup of adults with eczema. In this trial, there were

[©] Queen's Printer and Controller of HMSO 2015. This work was produced by Pickett *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

no significant differences between those in the educational intervention group and those in the usual care control group. In one RCT of participants with acne the educational intervention did not demonstrate positive effects on HRQoL. In an educational intervention aimed at people with chronic pruritic skin diseases (including atopic dermatitis, psoriasis and chronic urticaria) the focus was to help participants cope with the associated itch of the condition. No benefit in terms of HRQoL was demonstrated at the 9-month follow-up period. Other outcomes reported in the included studies, such as disease severity outcomes, showed mixed results.

Cost-effectiveness

Three studies were included in the systematic review. Two were cost-effectiveness studies and one was a cost analysis. The nature of the interventions and comparators varied and the populations of interest across the included studies were children and adolescents in two studies and in adults in one study. None of the studies reported HRQoL in terms of quality-adjusted life-years (QALYs) gained. The two cost-effectiveness studies were based in the Netherlands and the cost analysis study was conducted in the UK. In general, the studies provided detailed information on the resources used and unit costs. Two of the three included studies provided resource use data that could be used to inform a future de novo cost-effectiveness model. The UK-based cost analysis was conducted from the NHS perspective; however, details of data inputs in terms of QALYs and costs were not reported. It is therefore difficult to draw conclusions on the results of the analysis.

Owing to the limitations in the included studies, it is uncertain whether educational interventions are cost-effective in the treatment of chronic inflammatory skin diseases.

To inform future modelling in this area, these three included studies, and four additional studies that had been retrieved for screening for inclusion into the systematic review of cost-effectiveness but not included, were scrutinised in more detail to determine the resources and costs used. There was heterogeneity between these studies; however, the range of relevant resources can be grouped under three broad categories – interventional, service use, non-service use – and these are discussed. A second area of focus from the overview of these seven studies to inform future modelling was in terms of the choice of outcomes. Again, heterogeneity between the studies meant that making conclusions was difficult; however, the report makes recommendations for the choice of outcome measure in any future studies that include the use of preference-based generic measures of HRQoL or disease-specific measures of HRQoL that can be mapped to generic measures.

Discussion

Commonalities between effective interventions were a long delivery period (ranging from 6 weeks to 3 months) and delivery by a multidisciplinary team; however, this was not tested in any way and it remains uncertain from the current evidence base which elements of educational interventions may be associated with improvements in HRQoL. Our review has identified a number of gaps in the clinical effectiveness and cost-effectiveness evidence base. In particular, no studies focused on the less common skin conditions. In addition, approximately one-third of the evidence that met our eligibility criteria did not provide adequate information about the results and could not be included. Few of the studies that were included reported adequate details of the intervention, such as the aim or the theoretical basis. This indicates the need for better reporting in this research area.

Strengths of our research are that the systematic reviews were conducted in line with good practice following a published protocol. A limitation to the review is that the application of the inclusion criterion around whether the interventions were aimed at improving HRQoL, or the inference that they could improve HRQoL, was rarely reported.

Conclusions

Overall, there is uncertainty over whether or not educational interventions addressing issues that could improve HRQoL in people with chronic inflammatory skin conditions are effective. Tentative conclusions about the best approach to delivering these kinds of interventions are that face-to-face, group sessions may be beneficial; however, evidence also suggests that text messages may be effective. There are some indications that delivery over a period ranging from 6 weeks to 3 months and delivery by a multidisciplinary team may also be associated with positive outcomes. Based on available evidence, there is uncertainty over whether or not educational interventions are cost-effective in terms of improving HRQoL. Priorities for research are high-quality, adequately powered RCTs that evaluate theory-based interventions and include an adequate long-term follow-up in all chronic inflammatory skin conditions. Ideally, such RCTs should include an economic evaluation and a process evaluation.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

© Queen's Printer and Controller of HMSO 2015. This work was produced by Pickett *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Health Technology Assessment

ISSN 1366-5278 (Print)

ISSN 2046-4924 (Online)

Impact factor: 5.116

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the ISI Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: nihredit@southampton.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in *Health Technology Assessment* (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in *Health Technology Assessment* are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 13/11/01. The contractual start date was in January 2014. The draft report began editorial review in October 2014 and was accepted for publication in April 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen's Printer and Controller of HMSO 2015. This work was produced by Pickett *et al.* under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).

Editor-in-Chief of *Health Technology Assessment* and NIHR Journals Library

Professor Tom Walley Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

Professor Aileen Clarke Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

Dr Tessa Crilly Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson Director of NETSCC, HTA, UK

Ms Tara Lamont Scientific Advisor, NETSCC, UK

Professor Elaine McColl Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK

Professor John Norrie Health Services Research Unit, University of Aberdeen, UK

Professor John Powell Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Helen Snooks Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk